The Audited Financial Results for the quarter and year ended March 31, 2026 and recommendation of Final Dividend of Rs. 18 /- per equity share i.e. 900 % of the Face Value of Rs. 2/- each ....
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Lupin Ltd reported strong FY2026 results with standalone revenue growing 15% to Rs. 195.1 billion and consolidated revenue rising 23% to Rs. 279.6 billion year-on-year. Standalone net profit surged 60% to Rs. 63.7 billion while consolidated net profit increased 62% to Rs. 53.6 billion. EPS (basic, consolidated, after exceptional items) improved from Rs. 71.95 to Rs. 116.75. The Board recommended a dividend of Rs. 18 per share (900% of face value). Key exceptional items include antitrust litigation provisions of Rs. 5.8 billion, Astellas settlement costs of Rs. 8.5 billion, gains from divestments of Rs. 6.6 billion, and new labour code implementation costs of Rs. 512 million. The company completed acquisitions of VISUfarma B.V. and Renascience Pharma Limited. Cash flow from operations was strong at Rs. 73.3 billion on consolidated basis. Auditors B S R & Co. LLP gave an unmodified (clean) opinion.
Lupin delivered robust profit growth exceeding 60% with healthy operating cash flows, signaling strong business recovery. The clean audit opinion removes concerns about financial reporting quality. However, shareholders should note ongoing antitrust litigation provisions and settlement costs represent contingent risks.